Przejdź do zawartości
Merck

SML0146

Sigma-Aldrich

ZL006

≥98% (HPLC)

Synonim(y):

4-((3,5-Dichloro-2-hydroxybenzyl)amino)-2-hydroxybenzoic acid

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór empiryczny (zapis Hilla):
C14H11Cl2NO4
Numer CAS:
Masa cząsteczkowa:
328.15
Numer MDL:
Kod UNSPSC:
12352200
Identyfikator substancji w PubChem:
NACRES:
NA.25

Poziom jakości

Próba

≥98% (HPLC)

Postać

powder

kolor

white to tan

rozpuszczalność

DMSO: ≥5 mg/mL (warmed to 60° C)

temp. przechowywania

2-8°C

ciąg SMILES

OC1=C(Cl)C=C(Cl)C=C1CNC(C=C2)=CC(O)=C2C(O)=O

InChI

1S/C14H11Cl2NO4/c15-8-3-7(13(19)11(16)4-8)6-17-9-1-2-10(14(20)21)12(18)5-9/h1-5,17-19H,6H2,(H,20,21)

Klucz InChI

RTEYSQSXRFVKTJ-UHFFFAOYSA-N

Działania biochem./fizjol.

ZL006 inhibits the ischemia-induced interaction of nNOS with postsynaptic density protein-95 (PSD-95), preventing glutamate-induced excitotoxicity and cerebral ischemic damage. It does not inhibit nNOS itself. ZL006 is brain penetrant, and has been tested in both rat and mouse models of stroke.
ZL006, a novel neuroprotectant, is also called as 5-(3, 5-dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid. It has the ability to block the interaction of neuronal nitric oxide synthase (nNOS)/postsynaptic density protein-95 (PSD-95) in co-immunoprecipitation assays of extracts from glutamate or cultured neurons and cortical brain, stimulated by ischemia.
This page may contain text that has been machine translated.

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Sandra Tillmann et al.
PloS one, 12(8), e0182698-e0182698 (2017-08-05)
N-methyl-D-aspartate receptor (NMDA-R) antagonists and nitric oxide inhibitors have shown promising efficacy in depression but commonly induce adverse events. To circumvent these, a more indirect disruption of the nitric oxide synthase/postsynaptic density protein 95 kDa complex at the NMDA-R has
Wenrui Qu et al.
Cerebral cortex (New York, N.Y. : 1991), 30(7), 3859-3871 (2020-01-29)
Excessive activation of N-methyl-D-aspartate receptors (NMDARs) and the resulting neuronal nitric oxide synthase (nNOS) activation plays a crucial role in the pathogenesis of traumatic brain injury (TBI). However, directly inhibiting NMDARs or nNOS produces adverse side effects because they play
Xiaoli Gu et al.
Journal of separation science, 40(17), 3522-3534 (2017-07-14)
In the scope of stroke treatment, new neuronal nitric oxide synthase-postsynaptic density protein-95 uncouplers from herbal medicines were discovered and captured. To do so, highly selective magnetic molecularly imprinted polymers with a core-shell structure were prepared as artificial antibodies. According
Peng Luo et al.
Cell death & disease, 10(7), 496-496 (2019-06-27)
Traumatic brain injury (TBI) has become a major health concern worldwide, and the poor outcome of TBI increases the need for therapeutic improvement. Secondary injuries following TBI, including excitotoxicity, lead to synaptic dysfunction and provide potential targets for intervention. Postsynaptic
Satoshi Deyama et al.
Neuropharmacology, 118, 59-68 (2017-03-13)
Pain consists of sensory and affective components. Although the neuronal mechanisms underlying the sensory component of pain have been studied extensively, those underlying its affective component are only beginning to be elucidated. Previously, we showed the pivotal role of the

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej